Trophoblast cell surface antigen 2 (TROP2), also known as GA733-1 or EGP-1 or TACSTD2, was a 36-kDa transmembrane glycoprotein, which was originally defined on normal and malignant trophoblast cells[@b1][@b2][@b3]. TROP2 has four potential N-linked glycosylation sites, and consists of 323 amino acids[@b4]. Trop-2 was synthesized in the endoplasmic reticulum, transported to, and glycosylated in the Golgi apparatus, and then sorted to the cell membrane[@b5]. Trop-2 was a calcium signal transducer that drives tumor growth and as quantitative tumor driver[@b3][@b5]. Existing evidences have shown that it plays a functional role in cancer progression and stem cells[@b6][@b7]. Altered expression and/or activity of TROP2 was involved in cancer cell growth, proliferation, migration, invasion and survival[@b8][@b9][@b10][@b11][@b12][@b13]. An increasing number of studies suggested that TROP2 is highly expressed in solid tumors, including gastric cancer[@b14][@b15], nasopharyngeal carcinoma[@b16], gallbladder cancer[@b17], cervical cancer[@b18], extranodal NK/T cell lymphoma[@b11], lung cancer[@b9][@b19], laryngeal squamous cell carcinoma[@b20], colon cancer[@b21][@b22][@b23], Hilar Cholangiocarcinoma[@b24], pancreatic cancer[@b25], squamous cell carcinoma of the oral cavity[@b26], endometrioid endometrial carcinoma[@b27], ovarian carcinoma[@b28]. These striking evidences on the role of TROP2 in cancer suggest the transmembrane glycoprotein would be further considered as a potential marker for outcome of cancer patients.

Many studies showed that increased TROP2 expression in tumor tissues was correlated with poor survival of patients with various cancer types. However, the results of those individual studies were not comprehensive. In the present study, we performed this comprehensive meta-analysis aiming to clarify the prognostic value of TROP2 in solid tumors and to support that the protein may be a potential therapeutic oncotarget.

Materials and Methods
=====================

Publication search
------------------

This present meta-analysis was performed under the Preferred Reporting Items for Systematics Reviews and Meta-Analyses guidelines[@b29]. A comprehensive literature search was performed using the electronic databases PubMed, Embase, and Web of Science databases (up to April 7, 2016) with the search terms: 'TROP2', 'Trophoblast cell surface antigen 2′ and "cancer"/"tumor"/"neoplasm"/"carcinoma" and the following limits: Human, article in English or Chinese. All potentially eligible studies were retrieved and their bibliographies were carefully scanned to identify other eligible studies and extra studies were identified by a hand search of the references cited in the original studies. When multiple studies of the same patient population were identified, we included the published report with the largest sample size.

Inclusion criteria
------------------

To be eligible for inclusion in this meta-analysis and data extraction, studies had to: (a) evaluation of TROP2 expression for predicting prognosis in cancer, (b) provide hazard ratios (HRs) with 95% confidence intervals (CIs) or enable calculation of these statistics from the data presented (c) classify TROP2 expression as "high" and "low" or "positive" and "negative". (d) studies published in English.

Exclusion criteria
------------------

Exclusion criteria were: (a) literatures published as letters, editorials, abstracts, reviews, case reports and expert opinions; (b) experiments performed *in vitro* or *in vivo*, but not based on patients; (c) articles without the HRs and 95% CI or K-M survival curves dealing with overall survival, disease-free survival; (d) The follow-up duration was shorter than 3 years.

Data extraction
---------------

All data from the included studies were extracted independently and carefully by two reviewers using a standardized form. Disagreement was resolved through independently extracting data from the original article by the third author, and consensus was reached by discussions. The meta-analysis of TROP2 expression was based on two outcome endpoints: OS and DFS. Several different parameters, if reported, were extracted from each paper, including the first author's surname, publication year, country of origin, number of patients analyzed, types of measurement, and score for TROP2 assessment, cut-off values to determine TROP2 overexpression, OS and DFS. The main features of these eligible studies are summarized in [Table 1](#t1){ref-type="table"}. OS was defined as the interval between initial diagnosis and death. DFS was the interval between initial diagnosis and recurrent or between disease progress and death. The multivariate HR was extracted to assess prognostic value of TROP2 expression. For the articles in which prognosis was plotted only as the Kaplan-Meier curves, the Engauge Digitizer V4.1 was then used to extract survival data, and the estimates of the HRs and 95% CIs were calculated by Tierney's method[@b30]. All studies were assessed by Newcastle-Ottawa Scale (NOS). The quality scores ranged from 6 to 8, suggesting that the methodological quality was high.

Statistical analysis
--------------------

The data collected from each qualified paper of outcomes was used to evaluate the associations between TROP2 expression and solid cancer prognosis through meta-analysis. Pooled HRs and 95% CIs for two outcome endpoints (OS, DFS) were calculated. Subgroup analysis was performed when there were at least three studies in each subgroup. Statistical heterogeneity was assessed using the Q test, and a *P* value \> 0.10 suggested a lack of heterogeneity among studies. We also quantified the effect of heterogeneity using *I*^2^ = 100% × (Q − df)/Q. *I*^2^ values of \<25% may be considered "low", values of about 50% may be considered "moderate" and values of \>75% may be considered "high"[@b31]. According to the absence or presence of heterogeneity, random effects model or fixed effects model was used to merge the HR, respectively. Without statistical heterogeneity, a fixed effects model was employed to calculate the pooled HRs, otherwise random effects model was used[@b32]. Funnel plots and the Egger's test were employed to estimate the possible publication bias[@b33]. If a publication bias did exist, its influence on the overall effect was assessed by the Duval and Tweedie's trim and fill method[@b34]. Sensitivity analysis was also conducted to find out if certain single article could influence the overall result. Statistical analyses were conducted using Stata 14.0 (StataCorp, College Station, TX). P values for all comparisons were two-tailed and statistical significance was defined as p \< 0.05 for all tests, except those for heterogeneity.

Results
=======

Demographic characteristics
---------------------------

A total of 126 articles were retrieved by a literature search of the PubMed, Embase, and Web of Science databases, using different combinations of key terms. As showed in the search flow diagram ([Fig. 1](#f1){ref-type="fig"}), 126 records were initially retrieved using the predefined search strategy. Because of repeated data, 50 records were removed. After browsing the retrieved titles and abstracts, 56 records were excluded due to no relevant endpoint provided. The remaining 22 records were downloaded as full-text and carefully accessed one by one. Among them, 6 studies were excluded, including one study that was experimental study, four that without prognosis data, one in chinese. As a result, 16 published studies including 2,569 patients that met the inclusion norm were finally selected for the meta-analysis, which assessed the relevance between TROP2 expression and solid tumor prognosis. The median sample-size was 97, with a wide range from 26 to 620. Among all cohorts, Mongoloid (n = 11) became the major race of literatures, followed by Caucasian (n = 5). As for the cancer type, twostudies evaluated gastric cancer, one study evaluated nasopharyngeal carcinoma, one study evaluated gallbladder cancer, one study evaluated cervical carcinoma, one study evaluated extranodal NK/T cell lymphoma, two studies evaluated lung cancer, one study evaluated laryngeal squamous cell carcinoma, one study evaluated Hilar Cholangiocarcinoma, two studies evaluated colorectal cancer, one study evaluated pancreatic cancer, one study evaluated squamous cell carcinoma of the oral cavity, one study evaluated endometrioid endometrial carcinoma, one study evaluated ovarian carcinoma. Overall, 15 studies focused on OS, 6 studies focused on DFS.

Evidence synthesis
------------------

The meta-analysis of TROP2 expression was based on two outcome endpoints: OS, DFS. 15studies were included in the meta-analysis of OS. A fixed effects model was utilized to calculate the pooled hazard ratio (HR) and 95% confidence interval (CI) on account of the heterogeneity test reported a P value of 0.677 and an *I*^2^ values of 0.0%. The results suggested that TROP2 overexpression was associated with poor OS of solid tumors (pooled HR = 1.896, 95% CI = 1.599--2.247, *P* \< 0.001) ([Fig. 2](#f2){ref-type="fig"}). 6 studies were included in the meta-analysis of DFS. Owing to the heterogeneity test reported a P value of 0.210 and an *I*^2^ values of 30.0%, a fixed-effects model was used. The results show a significant association between TROP2 expression and DFS (pooled HR = 2.336, 95% CI = 1.596--3.419, *P* \< 0.001) ([Fig. 3](#f3){ref-type="fig"}). Subgroup study was then performed, the results suggested that the associations between TROP2 overexpression and poor OS and poor DFS were significant in Mongoloid patients (OS: pooled HR = 1.841, 95% CI 1.507--2.250, *P* \< 0.001; DFS: pooled HR = 2.112, 95% CI = 1.299--3.433, *P* = 0.003), as well as in Caucasian (OS: pooled HR = 2.042, 95% CI 1.482--2.814, *P* \< 0.001; DFS: pooled HR = 2.745, 95% CI 1.485--5.072, *P* = 0.001). The results showed that there was no difference OS or DFS HR across populations of different descent. The significant association was also detected between TROP2 overexpression and poor outcome in patients with female genital system neoplasms (OS: pooled HR = 1.989, 95% CI = 1.312--3.015, *P* = 0.001; DFS: pooled HR = 1.904, 95% CI = 1.227--2.954, *P* = 0.004) and gastrointestine neoplasms(OS: pooled HR = 1.642, 95% CI = 1.104--2.444, *P* = 0.014).

Publication bias and sensitivity analysis
-----------------------------------------

Begg's funnel plot and Egger's test were utilized to estimate the publication bias of the included literatures. The shapes of the funnel plots for the OS and DFS showed no evidence of obvious heterogeneity ([Fig. 4](#f4){ref-type="fig"}), and Egger's tests revealed publication bias concerning OS (P = 0.061) but not DFS (P = 0.653). Therefore, we performed trim and fill method to make pooled HR more reliable, and the P value was also \<0.01(data not shown). Sensitivity analyses were further performed to determine the robustness of the results described above. No individual study dominated this meta-analysis, and the removal of any single study had no significant effect on the overall conclusion ([Fig. 5](#f5){ref-type="fig"}).

Discussions
===========

High TROP2 expression had been reported to promote cancer progression and predict of poor prognosis of cancer patients[@b13][@b18][@b24][@b25][@b35]. Many clinical studies investigated the prognostic value of TROP2 over-expression. Most of these studies, however, include only limited numbers of patients and their conclusions remain not comprehensive. This current meta-analysis is the first complete overview of all reported clinical studies exploring the impact of TROP2 expression on prognosis of many solid tumors.

We systematically evaluated survival data of 2,569 solid tumor patients included in 16 different studies. Overall, these results clearly show that high TROP2 expression was a poor prognostic factor in solid tumors, with both results of poor OS (pooled HR = 1.896, 95% CI = 1.599--2.247, *P* \< 0.001) and poor DFS (pooled HR = 2.336, 95% CI = 1.596--3.419, *P* \< 0.001). Similarly, subgroup analysis revealed the associations between TROP2 overexpression and poor OS and DFS were significant within Mongoloid and Caucasian. When data was stratified according to cancer types, the results showed the prognostic value of TROP2 over-expression was significant in female genital system neoplasms and in gastrointestine neoplasms.

To our knowledge, the present study is the first and most full-scale meta-analysis systemically exploring the possible prognostic role of TROP2 up-regulation in solid tumors. Our quantitative results strongly supported the current mainstream viewpoint that an undesirable impact of TROP2 redundancy was correlated with the OS and DFS.

Additionally, several important implications in this meta-analysis were displayed. First, high TROP2 expression may be a general poor prognostic marker in solid tumors. In this meta-analysis, we included thirteen different cancer types, including gastric cancer[@b14][@b15], nasopharyngeal carcinoma[@b16], gallbladder cancer[@b17], cervical cancer[@b18], extranodal NK/T cell lymphoma[@b11], lung cancer[@b9][@b19], laryngeal squamous cell carcinoma[@b20], Hilar Cholangiocarcinoma[@b24], colon cancer[@b21][@b22], pancreatic cancer[@b25], squamous cell carcinoma of the oral cavity[@b26], ovarian carcinoma[@b28], endometrioid endometrial carcinoma[@b27]. The pooled results from these cancer types demonstrated that high TROP2 expression was associated with poor OS and DFS, and this finding can be extended to all solid tumors. Second, we demonstrated that high TROP2 expression correlated with poor OS and DFS in Mongoloid and Caucasian patients, as well in female genital system neoplasms and in gastrointestine neoplasms. Finally, it underlines the potential to develop TROP2 as a valuable therapeutic target and prognostic biomarker for solid tumors.

Apart from the inspiring outcomes, limitations still lay in this quantitative meta-analysis. First of all, most of the included studies were designed as retrospective studies, and such studies are more likely to be published if they have positive results than if they have negative results. Furthermore, the method for assessing TROP2 expression and definition of TROP2 positivity were inconsistent. Besides, some studies did not provide complete data[@b36] or published in English[@b23] were excluded in statistics. Therefore, our estimate of the associations between increased TROP2 and outcomes may have been overestimated.

In conclusion, high TROP2 expression in solid tumor tissues association with poor survival was clearly demonstrated in the present meta-analysis. We suggest that TROP2 may be a useful prognostic biomarker and a promising therapeutic target for solid tumors. Nevertheless, further studies related to specific tumor types and perspectives are required to corroborate the clinical utility of TROP2 expression in solid tumors.
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###### Characteristics of studies included in the meta-analysis.

  Author         Year  Country        Case  Disease                                      Method   Cut off value                                           Endpoints    NOS
  ------------- ------ ------------- ------ -------------------------------------------- -------- ------------------------------------------------------- ----------- -----
  Zhao W         2015  China           26   gastric cancer                               IHC      score \> 0(range of 0--300)                             OS            6
  Guan GF        2015  China           58   nasopharyngeal carcinoma                     IHC      Low = score 0--1.5;high = score 2--3                    OS, DFS       8
  Chen MB        2014  china           70   gallbladder cancer                           IHC      low (0--3) or high (4--9)                               OS            8
  Liu T          2013  China           74   Cervical Cancer                              IHC      score \> 0(range of 0--9)                               OS, DFS       9
  Chen RJ        2013  China           90   extranodal NK/T cell lymphoma, nasal type    IHC      HIS ≥ 4(range of 0--12)                                 OS            8
  Pak MG         2012  South Korea     93   non-small cell lung cancer -adenocarcinoma   IHC      score \> 4(range of 0--12)                              OS,DFS        7
  Wu H           2012  China           95   laryngeal squamous cell carcinoma            IHC      score \> 0(range of 0--9)                               OS            9
  Ning SL        2012  China           97   Hilar Cholangiocarcinoma                     IHC      score \> 4(range of 0--12)                              OS            9
  Bignotti E     2012  Italy          100   endometrioid endometrial carcinoma           ICH      score = 3                                               OS,DFS        7
  Bignotti E     2010  Italy          104   ovarian carcinoma                            ICH      score = 3                                               OS,DFS        8
  Kobayashi H    2010  Japan          106   pulmonary adenocarcinoma                     IHC      score \> 4(range of 0--12)                              OS            8
  Fang YJ        2009  China          109   colon cancer                                 IHC      immunoreactivity rating of II or III; moderate/strong   OS            9
  Mühlmann G     2008  Austria        130   intestinal-type gastric cancer               IHC      score ≥ 4(range of 0--12)                               DFS           9
  Fong D         2008  Austria        197   pancreatic cancer                            IHC      score ≥ 4(range of 0--12)                               OS            7
  Fong D         2008  Austria        600   squamous cell carcinoma of the oral cavity   IHC      score ≥ 4(range of 0--12)                               OS            8
  Ohmachi T      2006  Japan          620   Colorectal Cancer                            RT-PCR   \>95% of the expression values of the normal samples    OS            7

ICH:Immunohistochemistry.
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